Business Description
Vigonvita Life Sciences is a China-based biopharmaceutical company focused on developing small molecule treatments for mental health conditions, sexual health, and viral infections. Founded in 2013 and headquartered in Suzhou, the company has built a broad pipeline of drug candidates at various stages of clinical testing, covering conditions such as depression, erectile dysfunction, epilepsy, schizophrenia, and several viral diseases including COVID-19. Its most advanced programs include TPN171, which has completed Phase III trials for erectile dysfunction, and VV116, an antiviral compound studied against both respiratory syncytial virus and COVID-19.
